Nectar Lifesciences Ltd
Nectar Lifesciences Ltd (NECLIFE) last traded at ₹11.3, a market capitalisation of ₹220 crore. Over the past 52 weeks the stock has ranged between ₹9.2 and ₹22.5. Nectar Lifesciences Ltd last reported results for the quarter ended Jun 2026, with sales of ₹0 crore and net profit of ₹-15 crore. Nectar Lifesciences Ltd’s annual general meeting is scheduled for 16 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Nectar Lifesciences Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Nectar Lifesciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹0 cr, down 100.0% from ₹5 cr a year earlier. Net profit was ₹-15 cr, up 76.2% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 6 | 0 | 0 | 5 | 1 | 0 | 1 | 0 |
| Expenses | 6 | 0 | 0 | 6 | 0 | 2 | 59 | 28 |
| Operating profit | -1 | -0 | -0 | -1 | 1 | -2 | -57 | -27 |
| OPM % | -10% | -500% | -500% | -16% | 77% | — | -4,437% | -6,198% |
| Other income | 7 | 8 | -130 | -62 | -176 | 35 | -24 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 30 | 6 | 0 |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Profit before tax | 5 | 8 | -130 | -64 | -176 | 3 | -88 | -24 |
| Tax % | -2% | 2% | -0% | -1% | 0% | -339% | -22% | -37% |
| Net profit | 6 | 8 | -130 | -63 | -176 | 14 | -68 | -15 |
| EPS (₹) | 0.25 | 0.35 | -5.80 | -2.82 | -7.85 | 0.64 | -3.50 | -0.79 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Nectar Lifesciences Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 1,541 | 1,665 | 1,520 | 1,682 | 1,664 | 0 | 2 |
| Operating profit | 109 | 159 | 53 | 152 | -30 | -8 | -86 |
| OPM % | 7% | 10% | 3.5% | 9% | -1.8% | -2,920% | -3,520% |
| Net profit | -73 | 25 | -24 | 5 | -114 | -293 | -245 |
| EPS (₹) | -3.27 | 1.12 | -1.08 | 0.22 | -5.07 | -15.08 | -11.50 |
TTM is the trailing twelve months to the most recent quarter.
Nectar Lifesciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -78%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -9161%
- 10 Years
- -12%
- 5 Years
- -20%
- 3 Years
- -25%
- 1 Year
- -30%
- 10 Years
- -3%
- 5 Years
- -8%
- 3 Years
- -12%
- Last Year
- -31%
Nectar Lifesciences Ltd shareholding pattern
Promoters held 51.84% at Jun 2026, up from 44.53% at Jun 2025. FIIs 0.50% and DIIs 0.01%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 55.80% | 44.53% | 44.53% | 44.53% | 44.91% | 44.91% | 51.84% | 51.84% |
| FIIs | 3.24% | 0.73% | 1.65% | 0.82% | 0.62% | 0.52% | 0.60% | 0.50% |
| DIIs | 0.00% | 0.00% | 0.15% | 0.19% | 0.08% | 0.00% | 0.01% | 0.01% |
| Government | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 5.84% | 4.03% | 3.75% |
| Public | 40.94% | 54.72% | 53.64% | 54.45% | 54.37% | 48.73% | 43.52% | 43.90% |
| No. of shareholders | 66,741 | 69,482 | 69,241 | 71,977 | 76,470 | 78,124 | 74,834 | 73,834 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Nectar Lifesciences Ltd’s AGM?
Nectar Lifesciences Ltd’s annual general meeting is scheduled for 16 Sept 2026.
- AGM31st Annual General Meeting, e-voting, and book closure
- AGM31st Annual General Meeting and related resolutions
See the full results calendar for every Indian company reporting in the next 30 days.
Nectar Lifesciences Ltd corporate filings
- Letter Sent To MembersCompany Updatelow impact
Cruxal's analysis: Nectar Lifesciences has issued a formal communication to its members in compliance with…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Nectar Lifesciences has published a newspaper notice regarding its 31st Annual General…
Read the full analysis - Pursuant to Regulations 30 and 34 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copy of Annual ....Otherslow impact
Cruxal's analysis: Nectar Lifesciences has submitted its Annual Report for the financial year ended March…
Read the full analysis - Notice Of 31St Annual General Meeting ('AGM') For The Financial Year 2025-26AGM/EGMlow impact
Cruxal's analysis: Nectar Lifesciences Ltd. has issued a notice for its 31st Annual General Meeting (AGM) to…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Nectar Lifesciences Ltd. has issued a formal notice regarding its 31st Annual General…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatehigh impact
Cruxal's analysis: Nectar Lifesciences Limited has released its financial results for the quarter ended June…
Read the full analysis - Announcement under Regulation 30 (LODR)-Change in Corporate Office AddressCompany Updatelow impact
Cruxal's analysis: Nectar Lifesciences Ltd has filed a routine disclosure regarding a change in its…
Read the full analysis - AGM to be held on September 18, 2026 and book closure date for the same is from September 12, 2026 to September 18, 2026(both days inclusive). The Cut-off date, to ascertain the eligibility ....Corp. Actionlow impact
Cruxal's analysis: Nectar Lifesciences Ltd. has formally notified the stock exchanges regarding the closure…
Read the full analysis - Unaudited Standalone And Consolidated Financial Results For The Quarter Ended On June 30, 2026Resultmedium impact
Cruxal's analysis: Nectar Lifesciences Limited reported a consolidated net loss of 15.40 crore for the…
Read the full analysis - Nectar Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve the Unaudited Financial ....Board Meetinglow impact
Cruxal's analysis: Nectar Lifesciences Ltd. has formally notified the stock exchanges of a board meeting…
Read the full analysis - Announcement under Regulation 30 (LODR)-Resignation of DirectorCompany Updatelow impact
Cruxal's analysis: Nectar Lifesciences Ltd. has informed the stock exchanges that Dr. Surulichamy…
Read the full analysis - Sale And Surrender Of Leasehold Rights In Land Situated In JammuCompany Updatelow impact
Cruxal's analysis: Nectar Lifesciences has formally notified the exchange regarding the sale and surrender…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Nectar Lifesciences Ltd
Cruxal reads every Nectar Lifesciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.